2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…2019 American Transplant Congress
Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths
*Purpose: Many centers avoid the use of mTOR inhibitors (mTORi) in hypersensitized kidney transplant recipients and usually employ an immunosuppression based on Mycophenolic Acid (MPA),…2019 American Transplant Congress
Sex Specific Regulation of Podocyte-Specific Genes and Proteins Determines Glomerular Response to mTOR Inhibition
*Purpose: mTOR inhibitors are increasingly used in transplantation with high interindividual variation in proteinuric responses. Although males have higher prevalence and faster progression of glomerular…2019 American Transplant Congress
Sirolimus in Geriatric Kidney Transplantation: Modification of Outcomes by Pre-Transplant History of Malignancy or Cardiovascular Disease
*Purpose: We analyzed the outcomes associated with sirolimus (SRL)-regimens in geriatric (>/=65-year-old) kidney transplant recipients (KTRs).*Methods: Using 2000-2016 Scientific Registry of Transplant Recipients data, Cox…2018 American Transplant Congress
Lymph Node Reprogramming: Microparticle Delivery of Immune Signals to Induce Tolerance and Prolong Allograft Survival
Introduction: Microparticle (MP) loaded with peptide antigen plus other immune signals and delivered directly into lymph nodes (LN) can result in either pro-inflammatory or anti-inflammatory…2018 American Transplant Congress
TGF-b Plus Rapamycin Induce Foxp3 and Promote iTreg Development and Suppressive Function, Leading to Long-Term Allograft Survival
Path & Lab Med, CHOP & UPenn, Philadelphia, PA.
Given the major roadblocks to development of Treg-based cell therapy, pharmacologic approaches to expand endogenous Tregs warrant attention, including approaches with more sustained effects than…2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…2018 American Transplant Congress
Belatacept-Refractory CD8+CD28–CD38hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…2018 American Transplant Congress
Glycolytic Bias in mTORC2-Deficient Dendritic Cells Potentiates Antigen-Specific Immunity and Accelerates Graft Rejection
The mechanistic target of rapamycin (mTOR) is known to function in two complexes: mTOR complex 1 (mTORC1) and mTORC2. While the function of mTORC1 in…2018 American Transplant Congress
Rapamycin Impairs Human Endothelial Cell Alloimmunogenicity Independent of PD-1/PD-1 Ligand Inhibitory Signaling
Department of Surgery, Duke University Medical Center, Durham, NC.
Rapamycin prevents costimulation blockade (CoB)-resistant rejection in mice and primates, and early human data suggests a similar salutary effect. We have hypothesized that one mechanism…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »